Skip to main navigation menu Skip to main content Skip to site footer

No. 4 (2024)

GENERAL THERAPY QUESTIONS AND REVIEWS

Neuroinflammation Factors and Cognitive Deficits in Recurrent Depression: The Search for Pathogenetic and Therapeutic Targets

https://doi.org/10.21265/PSYPH.2024.61.34.003

Published 2024-12-30

  • M.G. Yanushko
    • ,
  • M.V. Shamanina

M.G. Yanushko
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Ministry of Heath of the Russian Federation

M.V. Shamanina
V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology of the Ministry of Heath of the Russian Federation

Abstract

Neuroinflammation is a possible pathogenetic mechanism of cognitive impairment in recurrent depressive disorder (RDD). The purpose of the undertaken narrative review was to analyze recent publications on the issue of neuroinflammation; an attempt was made to assess the role of various inflammatory factors in the course of depressive disorder and in cognitive impairment in patients suffering from depression. An analysis of the data available in the scientific literature on possible treatment of depressive symptoms and cognitive impairment from the perspective of neuroinflammatory mechanisms correction is provided. Scientific publications indicate that neuroinflammation plays an important role in the pathogenesis of RDD and the formation of cognitive deficit. Further research is needed on the possibilities of treatment interventions aimed to reduce the level of neuroinflammatory factors in order to correct cognitive impairment.

Keywords

depressive disorder, neuroinflammation, cytokines, cognitive impairment, neurometabolism

PDF (Русский)

References

  1. Кibitov A.A., Rakitko A.S., Kasyanov E.D., Rukavishnikov G.V., Kozlova K.A., Ilinsky V.V., Neznanov N.G., Mazo G.E., Kibitov A.O. Screening of depressive symptoms in a russian general population sample: A web-based cross-sectional study // Clin Pract Epidemiol Ment Health. – 2021. – Vol. 17. – Pр. 205–211. – https://doi.org/10.2174/1745017902117010205
  2. Chavez-Baldini U., Nieman D.H., Keestra A., Lok A., Mocking R.J.T., de Koning P., Krzhizhanovskaya V.V., Bockting C.L.H., van Rooijen G., Smit D.J.A., Sutterland A.L., Verweij K.J.H., van Wingen G., Wigman J.T.W., Vulink N.C., Denys D. The relationship between cognitive functioning and psychopathology in patients with psychiatric disorders: A transdiagnostic network analysis // Psychol Med. – 2021. – Vol. 24. – Pр. 1–10. – https://doi.org/10.1017/S0033291721001781
  3. Александровский Ю.А., Незнанов Н.Г. Психиатрия: национальное руководство. Краткое издание. – 2-е изд., перераб. и доп. – М.: ГЭОТАР-Медиа, 2021.
  4. Мосолов С.Н. Современные биологические гипотезы рекуррентной депрессии (обзор) // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2012. – Т. № 11-2. – С. 29–40.
  5. Chipurupalli S., Samavedam U., Robinson N. Crosstalk between ER stress, autophagy and inflammation // Front Med. – 2021. – Vol. 8. – Art. 758311. – https://doi.org/10.3389/fmed.2021.758311
  6. Wu D., Zhang G., Zhao C., Yang Y., Miao Z., Xu X. Interleukin-18 from neurons and microglia mediates depressive behaviors in mice with post-stroke depression // Brain Behav Immun. – 2020. – Vol. 88. – Pр. 411–420. – https://doi.org/10.1016/j.bbi.2020.04.004
  7. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis // Brain Behav Immun. – 2011. – Vol. 25. – Pp. 181–213.
  8. Rothwell N.J., Hopkins S.J. Cytokines and the nervous system II: Actions and mechanisms of action // Trends Neurosci. – 1995. – Vol. 18, no. 3. – Pp. 130–136. – https://doi.org/10.1016/0166-2236(95)93890-a
  9. Du X., Zou S., Yue Y., Fang X., Wu Y., Wu S. et al. Peripheral Interleukin-18 is negatively correlated with abnormal brain activity in patients with depression: A resting-state fMRI study // BMC Psychiatry. – 2022. – Vol. 22. – Art. 531. – https://doi.org/10.1186/s12888-022-04176-8
  10. Giollabhui N.M., Slaney C., Hemani G., Foley E., van der Most P., Nolte I., Snieder H., Davey Smith G., Khandaker G., Hartman C. Role of inflammation in depressive and anxiety disorders, affect, and cognition: Genetic and non-genetic findings in the lifelines cohort study // Res Sq [Preprint]. – 2024. – Aug 10. – Art. rs.3.rs-4379779. – https://doi.org/10.21203/rs.3.rs-4379779/v1
  11. Imaizumi T., Toda T., Maekawa M., Sakurai D., Hagiwara Y., Yoshida Y. et al. Identifying high-risk population of depression: association between metabolic syndrome and depression using a health checkup and claims database // Sci Rep. – 2022. – Vol. 12. – Art. 18577. – https://doi.org/10.1038/s41598-022-22048-9
  12. Lecca D., Jung Y.J., Scerba M.T., Hwang I., Kim Y.K., Kim S., Modrow S., Tweedie D., Hsueh S.C., Liu D., Luo W., Glotfelty E., Li Y., Wang J.Y., Luo Y., Hoffer B.J., Kim D.S., McDevitt R.A., Greig N.H. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis // Alzheimers Dement. – 2022. – Vol. 18, no. 11. – Pp. 2327–2340. – https://doi.org/10.1002/alz.12610.
  13. Kim Y.K., Kim O.Y., Song J. Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function // Front Pharmacol. – 2020. – Vol. 11. – Art. 1270. – https://doi.org/10.3389/fphar.2020.01270.
  14. Vitkovic L., Bockaert J., Jacque C. “Inflammatory” cytokines // Journal of Neurochemistry. – 2000. – Vol. 74. – Pр. 457–471. – https://doi.org/10.1046/j.1471-4159.2000.740457.x
  15. Delpech J.C., Valdearcos M., Nadjar A. Stress and microglia: A double-edged relationship // Adv Neurobiol. – 2024. – Vol. 37. – Pр. 333–342. – https://doi.org/10.1007/978-3-031-55529-9_18
  16. McAfoose B.T., Baune B.T. Evidence for a cytokine model of cognitive function // Neuroscience & Biobehavioral Reviews. – 2009. – Vol. 33, no. 3. – Pр. 355–366. – https://doi.org/10.1016/j.neubiorev.2008.10.005
  17. Livingston J.M., McDonald M.W., Gagnon T., Jeffers M.S., Gomez-Smith M., Antonescu S., Cron G.O., Boisvert C., Lacoste B., Corbett D. Influence of metabolic syndrome on cerebral perfusion and cognition // Neurobiol Dis. – 2020. – Vol. 137. – Art. 104756. – https://doi.org/10.1016/j.nbd.2020.104756
  18. Yates K.F., Sweat V., Yau P.L., Turchiano M.M., Convit A. Impact of metabolic syndrome on cognition and brain: a selected review of the literature // Arterioscler Thromb Vasc Biol. – 2012. – Vol. 32, no. 9. – Pp. 2060–2067. – https://doi.org/10.1161/ATVBAHA.112.252759
  19. Šimončičovа E., Henderson Pekarik K., Vecchiarelli H.A., Lauro C., Maggi L., Tremblay M.È. Adult neurogenesis, learning and memory // Adv Neurobiol. – 2024. – Vol. 37. – Pр. 221– 242. – https://doi.org/10.1007/978-3-031-55529-9_13
  20. Lamers F., Milaneschi Y., Vinkers C.H., Schoevers R.A., Giltay E.J., Penninx B.W.J.H. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study // Brain Behav Immun. – 2020. – Vol. 88. – Pр. 174–183. – https://doi.org/10.1016/j.bbi.2020.04.002
  21. Milaneschi Y., Lamers F., Berk M., Penninx B.W.J.H. Depression heterogeneity and Its biological underpinnings: Toward immunometabolic depression // Biol Psychiatry. – 2020. – Vol. 88, no. 5. – Pр. 369–380. – https://doi.org/10.1016/j.biopsych.2020.01.014
  22. Cho J.H., Irwin M.R., Eisenberger N.I., Lamkin D.M., Cole S.W. Transcriptomic predictors of inflammation-induced depressed mood // Neuropsychopharmacology. – 2019. – Vol. 44. – Pр. 923–929. – https://doi.org/10.1038/s41386-019-0316-9
  23. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell D. The role of cognitive impairment in general functioning in major depression // Psychiatry Res. – 2010. – Vol. 176, no. 2–3. – Pр. 183–189. – https://doi.org/10.1016/j.psychres.2008.12.001
  24. Rock P.L., Roiser J.P., Riedel W.J., Blackwell A.D. Cognitive impairment in depression: A systematic review and meta-analysis // Psychol Med. – 2014. – Vol. 44, no. 10. – Pр. 2029–2040. – https://doi.org/10.1017/S0033291713002535
  25. Beurel E., Toups M., Nemeroff C.B. The bidirectional relationship of depression and inflammation: Double trouble // Neuron. – 2020. – Vol. 107. – Pр. 234–256. – https://doi.org/10.1016/j.neuron.2020.06.002
  26. Горбунова А.П., Рукавишников Г.В., Касьянов Е.Д. и др. Исследование связи гематологических коэффициентов системного воспаления с клиническими характеристика депрессии у пациентов с аффективными расстройствами // Психическое здоровье в меняющемся мире: сб. тез. – СПб.: НМИЦ ПН им. В.М. Бехтерева, 2024. 12. – EDN CHKEKP
  27. Горбунова А.П., Рукавишников Г.В., Касьянов Е.Д. и др. Гематологические коэффициент системного воспаления как потенциальные биомаркеры суицида // Суицидология. 2024. – Т. 15, № 1 (54). – С. 31–52. https://doi.org/10.32878/suiciderus.24-15-01(54)-31-52. – EDN WNZVPH
  28. Fries G.R., Saldana V.A., Finnstein J., Rein T. Molecular pathways of major depressive disorder converge on the synapse // Mol Psychiatry. – 2023. – Vol. 28. – Pр. 284–297. – https://doi.org/10.1038/s41380-022-01806-1
  29. Mac Giollabhui N., Ng T.H., Ellman L.M., Alloy L.B. The longitudinal associations of inflammatory biomarkers and depression revisited: Systematic review, meta-analysis, and meta-regression // Mol Psychiatry. – 2021. – Vol. 26, no. 7. – Pр. 3302–3314. – https://doi.org/10.1038/s41380-020-00867-4
  30. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis // Psychosom Med. – 2009. – Vol. 71, no. 2. – Pр. 171– 186. – https://doi.org/10.1097/PSY.0b013e3181907c1b
  31. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctоˆt K.L. A meta-analysis of cytokines in major depression // Biol Psychiatry. – 2010. – Vol. 67, no. 5. – Pр. 446–457. – https://doi.org/10.1016/j.biopsych.2009.09.033
  32. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness // Prog Neuropsychopharmacol Biol Psychiatry. – 2011. – Vol. 35, no. 3. – Pр. 676–692. – https://doi.org/10.1016/j.pnpbp.2010.05.004
  33. Csala M., Kardon T., Legeza B., Lizаk B., Mandl J., Margittai Е., Puskаs F., Szаraz P., Szelеnyi P., Bаnhegyi G. On the role of 4-hydroxynonenal in health and disease // Biochim Biophys Acta. – 2015. – Vol. 1852, no. 5. – Pр. 826–838. – https://doi.org/10.1016/j.bbadis.2015.01.015
  34. Liu T., Zhong S., Liao X., Chen J., He T., Lai S., Jia Y. A Meta-Analysis of Oxidative Stress Markers in Depression // PLoS One. – 2015. – Vol. 10, no. 10. – e0138904. – https://doi.org/10.1371/journal.pone.0138904
  35. Romano A., Serviddio G., Calcagnini S., Villani R., Giudetti A.M., Cassano T., Gaetani S. Linking lipid peroxidation and neuropsychiatric disorders: Focus on 4-hydroxy-2-nonenal // Free Radic Biol Med. – 2017. – Vol. 111. – Pр. 281–293. – https://doi.org/10.1016/j.freeradbiomed.2016.12.046
  36. Chen M.H., Hsu J.W., Huang K.L., Tsai S.J., Su T.P., Li C.T., Lin W.C., Tu P.C., Bai Y.M. Role of obesity in systemic low-grade inflammation and cognitive function in patients with bipolar I disorder or major depressive disorder // CNS Spectr. – 2021. – Vol. 26, no. 5. – Pр. 521–527. – https://doi.org/10.1017/S1092852920001534
  37. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline // JAMA. – 2004. – Vol. 292, no. 18. – Pр. 2237–2242. – https://doi.org/10.1001/jama.292.18.2237
  38. Grassi-Oliveira R., Bauer M.E., Pezzi J.C., Teixeira A.L., Brietzke E. Interleukin-6 and verbal memory in recurrent major depressive disorder // Neuro Endocrinol Lett. – 2011. – Vol. 32, no. 4. – Pр. 540–544.
  39. Chang H.H., Lee I.H., Gean P.W., Lee S.Y., Chi M.H., Yang Y.K., Lu R.B., Chen P.S. Treatment response and cognitive impairment in major depression: association with C-reactive protein // Brain Behav Immun. – 2012. – Vol. 26, no. 1. – Pр. 90–95. – https://doi.org/10.1016/j.bbi.2011.07.239
  40. Krogh J., Benros M.E., Jørgensen M.B., Vesterager L., Elfving B., Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression // Brain Behav Immun. – 2014. – Vol. 35. – Pр. 70–76. – https://doi.org/10.1016/j.bbi.2013.08.014
  41. Jin K., Lu J., Yu Z., Shen Z., Li H., Mou T., Xu Y., Huang M. Linking peripheral IL-6, IL-1β and hypocretin-1 with cognitive impairment from major depression // J Affect Disord. – 2020. – Vol. 277. – Pр. 204–211. – https://doi.org/10.1016/j.jad.2020.08.024
  42. Sаnchez-Carro Y., de la Torre-Luque A., Portella M.J., Leal-Leturia I., Salvat-Pujol N., Massaneda C., de Arriba-Arnau A., Urretavizcaya M., Peretо M., Toll A., Martínez-Ruiz A., Ferreiros-Martinez R., Аlvarez P., Soria V., Lоpez-García P. Relationship between immunometabolic status and cognitive performance among major depression disorder patients // Psychoneuroendocrinology. – 2022. – Vol. 137. – Art. 105631. – https://doi.org/10.1016/j.psyneuen.2021.105631
  43. Vreijling S.R., Chin Fatt C.R., Williams L.M., Schatzberg A. F., Usherwood T., Nemeroff C.B., Rush A.J., Uher R., Aitchison K.J., Köhler-Forsberg O., Rietschel M., Trivedi M.H., Jha M.K., Penninx B.W.J.H., Beekman A.T.F., Jansen R., Lamers F. Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials // Br J Psychiatry. – 2024. – Vol. 224, no. 3. – Pр. 89–97. – https://doi.org/10.1192/bjp.2023.148
  44. Sampson E., Mills N.T., Hori H., Schwarte K., Hohoff C., Schubert O., Clark S.R., Fourrier C., Baune B.T. Exploratory analysis of the effects of celecoxib on cognitive function in vortioxetine-treated patients with major depressive disorder in the PREDDICT study: A randomized, double-blind, placebo-controlled clinical trial // J Clin Psychiatry. – 2023. – Vol. 84, no. 6. – Art. 23m14829. – https://doi.org/10.4088/JCP.23m14829
  45. Bai S., Guo W., Feng Y., Deng H., Li G., Nie H., Guo G., Yu H., Ma Y., Wang J., Chen S., Jing J., Yang J., Tang Y., Tang Z. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: A systematic review and meta-analysis of randomised controlled trials // J Neurol Neurosurg Psychiatry. – 2020. – Vol. 91, no. 1. – Pр. 21–32. – https://doi.org/10.1136/jnnp-2019-320912
  46. Varma M., Kaur A., Bhandari R., Kumar A., Kuhad A. Major depressive disorder (MDD): Emerging immune targets at preclinical level // Expert Opin Ther Targets. – 2023. – Vol. 27, no. 6. – Pр. 479–501. – https://doi.org/10.1080/14728222.2023.2225216
  47. Appleton K.M., Voyias P.D., Sallis H.M., Dawson S., Ness A.R., Churchill R., Perry R. Omega-3 fatty acids for depression in adults // Cochrane Database Syst Rev. – 2021. – Vol. 11, no. 11. – CD004692. – https://doi.org/10.1002/14651858.CD004692.pub5
  48. Köhler-Forsberg O., Otte C., Gold S.M., Østergaard S.D. Statins in the treatment of depression: Hype or hope? // Pharmacol Ther. – 2020. – Vol. 215. – Art. 107625. – https://doi.org/10.1016/j.pharmthera.2020.107625
  49. Anmella G., Meehan A., Ashton M., Mohebbi M., Fico G., Ng C.H., Maes M., Berk L., de Prisco M., Singh A.B., Malhi G.S., Berk M., Dodd S., Hidalgo-Mazzei D., Grande I., Pacchiarotti I., Murru A., Vieta E., Dean O.M. Exploring clinical subgroups of participants with major depressive disorder that may benefit from adjunctive minocycline treatment // Clin Psychopharmacol Neurosci. – 2024. – Vol. 22, no. 1. – Pр. 33–44. – https://doi.org/10.9758/cpn.23.1098

Downloads

Download data is not yet available.